Cambridge Heart — Investor Presentation (October 2011)
25 slides from Cambridge Heart's investor presentation, Oct 6, 2011
Slide 1: Specializing in Non-invasive Diagnosis of Life-Threatening Cardiac Disease
October 2011 Specializing in Non-invasive Diagnosis of Life-Threatening Cardiac Disease Symbol: CAMH.OB Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements 2 Statements in this presentation that are not purely historical are forward-looking statements. These forward- looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Forward-looking statements include statements a
Slide 3: Strategic Objectives
Strategic Objectives Impact the number of deaths from sudden cardiac arrest (SCA) from today’s 300,000 annual incidents Make Microvolt T-Wave Alternans (MTWA) testing a standard annual diagnostic assessment of 10 -12 million high-risk cardiac patients Leverage MTWA core technology into new, broader-
Slide 4: Lifetime Risk of Sudden Cardiac Arrest
Lifetime Risk of Sudden Cardiac Arrest “These results are the first estimates of lifetime risk for SCD…These relatively high lifetime risks (1 in 8 should promote public health and individual efforts aimed at preventing this devastating consequence of cardiovascular disease.” Lloyd-Jones DM, Berry J
Slide 5: High SCA Risk Population: Large US Market Opportunity
High SCA Risk Population: Large US Market Opportunity ~ 12 million high-risk individuals Circulation 2/10/2006 Heart Disease and Stroke Statistics 300,000 deaths per year 5 5 million Heart Failure 1-2 million other 8 million Post MI (Prior heart attack)
Slide 6: SCA Risk Management
SCA Risk Management Adapted from Myerburg, NEJM 2009; 360(9):938. 6 SCA risk can be managed if those at risk are identified
Slide 7: T-Wave Alternans (TWA)
T-Wave Alternans (TWA) • T-wave alternans (TWA) refers to alternating, beat- to-beat fluctuations in amplitude and/or morphology of the T wave. • TWA is associated with increased risk of ventricular tachyarrhythmias and sudden cardiac death. 7 Cambridge Heart’s proprietary technology is capable of d
Slide 8: Patented Technology
Patented Technology Analytic Spectral Method ® Segment 2 Impedance Respiration Segment 1 Enhanced ECG Noise Reduction Reduction of noise through adaptive cancellation of artifact using proprietary active sensors 8
Slide 9: Patent Portfolio
Patent Portfolio 9 13 issued domestic and international patents protect all components of the technology Patent protecting the core technology valid through 2021 3 pending patents on new applications – Proprietary multi-segment sensors – Recording device – Analysis algorithm – Interpretation softwar
Slide 10: Microvolt T-Wave Alternans (MTWA)
Microvolt T-Wave Alternans (MTWA) More effective at identifying at- risk SCA patients than invasive electrophysiology (EP) test Patients with a positive MTWA result are up to 14 times more likely to experience sudden cardiac arrest Patients with negative MTWA result have an extremely low risk of exp
Slide 11: Clinical Validation
Clinical Validation 200+ publications in peer-reviewed journals Large prospective clinical trials Applicable patient populations 11 – ALPHA Study - Boston Scientific – ABCD Study – St. Jude Medical – MASTER Study -- Medtronic – Ikeda Study – Meta Analysis – Hahnloser (March 2009 HRS Supplement) – Pr
Slide 12: Class IIa Guideline
Class IIa Guideline American College of Cardiology/American Heart Assoc./European Society of Cardiology 2006 Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (Developed in collaboration with the HRS and EHRA) – Class IIa It is reasonable to
Slide 13: CMS National Coverage
CMS National Coverage “CMS (Medicare) has determined that there is sufficient evidence to conclude that Microvolt T- wave Alternans (MTWA) diagnostic testing is for the evaluation of patients at risk of sudden cardiac death, only is used, and CMS is issuing the following national coverage determinat
Slide 14: CMS National Coverage: Original vs Revised Medicare Coverage
CMS National Coverage Original Medicare Coverage Revised Medicare Coverage 14 – Reimbursement was limited if MTWA is performed at the same time as standard stress, stress echo or nuclear stress testing – Negatively impacted physician’s ability to integrate MTWA testing for high-risk cardiac patients
Slide 15: StressPlus
StressPlus TM CPT 93025 CPT 93015 CPT 93015 15 Stress Testing Stress + MTWA vs. Assess Arrhythmic Risk Assess Ischemic Risk Assess Arrhythmic Risk Assess Ischemic Risk Microvolt T-wave Alternans Cardiovascular stress test Cardiovascular stress test StressPlus TM model helps to overcome common hurdle
Slide 16: Private Coverage
Private Coverage Current private coverage: Coverage typically for ICD indicated population Other private payers in progress 16 – United Healthcare – Aetna, Cigna, Humana – Blues: HCSC (IL, NM, OK, TX), Horizon (NJ), Care First (DC, DE, MD), Wellmark (IA, SD), Premera (AK, WA), BCBS of AZ, KS, MT, VT
Slide 17: Corporate Strategy: Product Positioning
Historical product positioning ~ 12 million post MI, HF and other high risk patients for SCA Primary prevention population (ICD candidates) Borderline/Reluctant ICD candidates Population at risk for SCA Population at risk for cardiac disease Corporate Strategy 17 Current OEM Module strategy Ischemia
Slide 18: OEM Module Strategy
OEM Module Strategy Provides MTWA technology as an add module to existing medical equipment vs. stand-alone product Taps into existing market for stress systems Materially reduces the acquisition cost Significantly simplifies practice integration Develops installed user base for expanded application
Slide 19: First OEM Partnership
First OEM Partnership Cardiac Science: US stress market leader Module is offered as an upgrade to: Product Launched September 2010 19 – 5 year, non-exclusive, worldwide – Partner will market and sell modules and sensors (CHI to drive utilization) – Partner’s new system sales – Partner’s existing ins
Slide 20: Additional Strategic Initiatives
Additional Strategic Initiatives MTWA Module – Other Stress Platforms MTWA Module – Other potential embodiments 20 – CHI’s current development work is portable to other manufacturer’s cardiac stress platforms – Ambulatory Holter platform – Event recording services
Slide 21: New Market Opportunity: Ischemia Application
New Market Opportunity Ischemia Application 21 ~ 12 million post MI, HF and other high risk patients for SCA – Data suggest MTWA can identify ischemia missed by other testing modalities – Feasibility study began in July 2010 – Data from several sites (including feasibility study sites) suggest MTWA
Slide 22: Financial Summary
Financial Summary Current Quarterly Revenue - $500,000 + 10% Quarterly Cash Expenditures - $1,700,000 + 10% Quarterly Cash Burn - $1,200,000 + 10% Cash as of June 30, 2011 – $1.6 million 22 – U.S. HearTwave Systems – U.S. Sensor revenue – All other (includes service and ROW sales) – Largely fixed ca
Slide 23: OEM Module Metrics
OEM Module Metrics Upfront Module Revenue Recurring Sensor Revenue Possible Range of Sensor Utilization/System 23 – $0 - $5,000 (platform/channel/promotion dependant) – COGS = $ 750 (low volume) – $45 - $70 per MTWA test (platform/channel dependant) – +70% gross margin – 70 to 140 sensors/module/yea
Slide 24: Capital Structure
Capital Structure Capital Structure (as converted) Series C-1 Convertible Preferred (SJM Mar 2007) Series D Convertible Preferred (Dec 2009) 24 – 125 million common shares issued and outstanding – 16 million warrants at $.25 – 10.2 million employee/director options (7 mm at $0.16 exercise price) – $
Slide 25: The Opportunity
The Opportunity Major components for success are in place, Risks associated with early stage medical devices are removed: Large addressable market No commercially viable competition High-margin (excess of 70%) razor- razorblade business model Ischemia potential opportunity 25 – FDA clearance, unique
Cambridge Heart — Investor Presentation (October 2011) on 6ix